# US 2025/0084156 A1 · Compositions and methods for treating synucleinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084156 A1
- Document ID: US20250084156A1
- Status: Published application
- Kind: A1
- Application number: 18/773,301
- Filed: 2024-07-15
- Published: 2025-03-13
- Earliest claimed: 2021-09-16
- Assignees: H.Lundbeck A/S
- Applicants: H.Lundbeck A/S
- Inventors: Henrik Rajesh Kumar PARSHAD; Anne Sofie MARKUSSEN; Mark Cornell MANNING; Derrick Spencer KATAYAMA; Magdalena GAUDEN; John SMITH
- Web page: https://patentgrep.com/patent/US20250084156A1

## CPC

- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C07K 16/18: against material from animals or humans
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A liquid pharmaceutical composition comprising a full length IgG1 monoclonal anti-alpha synuclein antibody in a concentration of 25-225 mg/mL, wherein said antibody comprises:
a. a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
b. a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:34;
c. a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
d. a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
e. a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
f. a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:6;
and wherein the composition further comprises histidine buffer, a pharmaceutically acceptable tonicity agent, a pharmaceutically acceptable surfactant and wherein the pH of the composition is between 5.5 to 6.5.

### Claim 28 (depends on 27)

The liquid pharmaceutical composition of claim 27, wherein the tonicity agent is selected from Mannitol, Sorbitol, Lactose, Dextrose, Trehalose, Sodium Chloride (NaCl), Potassium Chloride (KCl), Glycerol or Glycerine.

### Claim 29 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the tonicity agent is Sodium Chloride (NaCl).

### Claim 30 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the tonicity agent is Sodium Chloride (NaCl) in a concentration of about 100 mM.

### Claim 31 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the surfactant is selected from Polysorbate 20, Polysorbate 80, Poloxamer 188 or Triton X-100.

### Claim 32 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the surfactant is Polysorbate 80 in an amount of about 0.02%.

### Claim 33 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the concentration of the histidine buffer is about 25 mM.

### Claim 34 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the pHis 6.0.

### Claim 35 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the monoclonal anti-alpha synuclein antibody concentration is about 30-220 mg/mL.

### Claim 36 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the monoclonal anti-alpha synuclein antibody concentration is about 45-55 mg/mL.

### Claim at position 12

37-38. (canceled)

### Claim 39 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein the composition further comprises at least one bulking agent selected from Sucrose, Trehalose, Glucose, Lactose, Sorbitol, Mannitol, Glycerol, Arginine, Aspartic Acid, Glutamic acid, Glutamate, Lysine, Glycine, Histidine, Methionine, Alanine, Gelatin, PVP, PLGA, PEG, dextran, cyclodextrin and derivatives, starch derivatives, HSA or BSA.

### Claim 40 (depends on 39)

The liquid pharmaceutical composition according to claim 39, wherein the bulking agent is Arginine, Glutamate, Sucrose, Glycine or Sorbitol in a concentration of 100-200 mM.

### Claim 41

(canceled)

### Claim 42 (depends on 27)

The liquid pharmaceutical composition according to claim 27, comprising 53±5 mg/mL of the monoclonal anti-alpha synuclein antibody, 1.40 mg/mL L-Histidine, 3.34 mg/mL L-Histidine monohydrochloride, 34.16 mg/mL Sucrose, 5.83 mg/mL sodium chloride (NaCl), 0.20 mg/mL polysorbate 80 at pH 6.0.

### Claim 43

(canceled)

### Claim 44 (depends on 27)

The liquid pharmaceutical composition according to claim 27, comprising 53 mg/mL of the monoclonal anti-alpha synuclein antibody, 25 mM histidine buffer, 100 mM Sucrose, 100 mM sodium chloride (NaCl) or having amounts of each constituent within +/−20% of said values and 0.02% polysorbate 80 or having a concentration within +/−30% of said concentration, and having a pH of 6.0 or within +/−20% of said value.

### Claim 45

(canceled)

### Claim 46 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said liquid pharmaceutical composition is a stable liquid pharmaceutical composition.

### Claim 47 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said liquid pharmaceutical composition is a stable for at least 12 months when stored at 5° C.±3° C.

### Claim 48 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said liquid pharmaceutical composition is a stable for at least 24 months when stored at 5° C.±3° C.

### Claim 49 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said liquid pharmaceutical composition is a stable for at least 36 months when stored at 5° C.±3° C.

### Claim 50 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said liquid pharmaceutical composition is a low viscosity liquid pharmaceutical composition.

### Claim 51 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said liquid pharmaceutical composition is a low viscosity liquid pharmaceutical composition having a viscosity below 20 cP.

### Claim 52 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said liquid pharmaceutical composition is a low viscosity liquid pharmaceutical composition having a viscosity below 10 cP.

### Claim 53

(canceled)

### Claim 54 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said antibody comprises a heavy chain consisting of a variable domain of SEQ ID NO:31 and a light chain consisting of a variable domain of SEQ ID NO:8.

### Claim 55 (depends on 27)

The liquid pharmaceutical composition according to claim 27, wherein said antibody comprises a constant heavy chain domain as defined in SEQ ID NO:18 and a kappa light chain constant domain as defined in SEQ ID NO:17.
